Biomarker and morphological characteristics of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis

✍ Scribed by Imashuku, Shinsaku; Hibi, Shigeyoshi; Tabata, Yasuhiro; Sako, Masahiro; Sekine, Yuriko; Hirayama, Ken; Sakazaki, Hiromi; Maeda, Naoko; Kito, Hideyuki; Shichino, Hiroyuki; Mugishima, Hideo

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: English
• Weight: 302 KB
• Volume: 31
• Category: Article
• ISSN: 0098-1532
• DOI: 10.1002/(sici)1096-911x(199809)31:3<131::aid-mpo1>3.0.co;2-c

✦ Synopsis

Background.

Viruses may induce primary as well as secondary hemophagocytic lymphohistiocytosis (HLH), but it may not be possible to discriminate between these two in patients with a negative family history. Among these HLH cases, fulminant and fatal virus-associated hemophagocytic syndrome (VAHS) occurs mostly in relation to Epstein-Barr virus (EBV) infection. Although the immunological characteristics of EB-VAHS were previously reported, data on non-EB-VAHS were sporadic and fragmentary. This study has compared the clearly distinguishable groups of EBV-positive vs. EBVnegative HLH cases. Procedure. Among 26 patients with EBV-related HLH and 12 patients with non-EBV HLH, peripheral blood mononuclear cell (PBMC) subsets and serum concentrations of cytokines at the active phase of the disease were compared. Blood and bone mar-row smears were also compared. Results and Conclusions. The frequency of the CD3 + HLADR + subset in PBMC (median 34.3% vs. 4.8%), of serum concentrations of interferon (IFN)-␥ (median 105 U/ml vs. 2.4 U/ml), and of soluble interleukin-2-receptor (sIL-2R) (median 14,700 U/ml vs. 3,412 U/ml) were significantly different between these two groups. Morphological characteristics were noted for EBVrelated HLH cases. Mortality also differed between these two groups, 9/26 vs. 0/12 (P = 0.05). Data indicate pronounced immunological imbalance and poor prognosis in EBVrelated HLH cases. These parameters could be useful for determining an EBV involvement as well as risk factors in the early care and treatment of HLH patients. Med.